文献速递中医内科中医康复中药与中成药合理使用

特定外治中药疗法治疗卒中后吞咽障碍的系统评价与Meta分析

Systematic review and meta-analysis of specific external Chinese herbal medicines for post-stroke dysphagia: efficacy and clinical implications.
PubMed 文献 · Front Pharmacol · 2025-09-01

该系统评价纳入25项RCT共2159例卒中后吞咽障碍成人患者,比较特定外治中药疗法与常规非外治中药干预。Meta分析显示外治中药组在总有效率、治愈率、吞咽功能及营养指标等方面均优于对照组,安全性分析报告轻度皮肤刺激发生率为2.1%。

要点

  • 外治中药疗法可显著改善卒中后吞咽障碍患者的吞咽功能与营养状态。
  • 疗效具神经解剖特异性:大脑半球病变优选穴位贴敷,脑干病变优选中药离子导入。
  • 安全性分析仅3项研究报告轻度皮肤刺激(红斑、瘙痒)发生率2.1%。

核心结论

  • 特定外治中药疗法可显著改善卒中后吞咽障碍患者的吞咽功能、营养状况及临床结局。
  • 疗效呈现神经解剖特异性:大脑半球病变优选穴位,脑干受累优选中药离子导入。
  • 证据受方法学偏倚限制,尚需高质量RCT确认。

研究设计与样本

  • 系统评价与Meta分析,检索CNKI、VIP、WFSD、CBM及PubMed、Embase、Web of Science、Cochrane Library等数据库自建库至今。
  • 纳入25项RCT,共2159例患者,外治中药组1152例,对照组1007例。
  • 试验组接受特定外治中药疗法(如中药贴敷、离子导入、外敷、熏蒸)单独或联合常规护理,对照组接受常规治疗(康复、护理、药物)。
  • 采用Cochrane偏倚风险工具评估,RevMan 5.4进行Meta分析,按卒中病灶部位(幕上vs脑干)和干预类型进行分层亚组分析。

主要发现

  • 总有效率OR=3.28,95%CI [2.49, 4.31],外治中药组优于对照组。
  • 总治愈率OR=2.36,95%CI [1.84, 3.02],外治中药组优于对照组。
  • 饮水试验(WST)评分MD=-0.65,95%CI [-1.23, -0.06],外治中药组优于对照组。
  • 吞咽生活质量(SWAL-QOL)评分MD=25.61,95%CI [20.54, 30.67],外治中药组优于对照组。
  • 外治中药组在VFSS评分、MBI、血清白蛋白、前白蛋白、GUSS、ADL、FDS评分、胃管拔除成功率方面更优,NRS 2002评分更低、误吸发生率更低、胃管留置时间更短。

关键数值与推荐

  • 总有效率OR=3.28,95%CI [2.49, 4.31]。
  • 总治愈率OR=2.36,95%CI [1.84, 3.02]。
  • WST评分MD=-0.65,95%CI [-1.23, -0.06]。
  • SWAL-QOL评分MD=25.61,95%CI [20.54, 30.67]。
  • 安全性分析(3项研究)报告轻度皮肤刺激(红斑和瘙痒)发生率为2.1%。

临床怎么用

  • 可将特定外治中药疗法整合入卒中后吞咽障碍的康复方案。
  • 根据卒中病灶部位选择干预:大脑半球病变优先选用穴位贴敷,脑干病变优先选用中药离子导入。
  • 应用时关注皮肤不良反应,如红斑和瘙痒。

局限性

  • 证据受方法学偏倚限制,需高质量RCT进一步确认。
  • 安全性分析仅基于3项研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To systematically evaluate the efficacy and safety of specific external traditional Chinese medicine therapies (SETCM therapies) versus conventional non-SETCM therapy interventions for improving swallowing function, nutritional status, and reducing complications in adult patients with post-stroke dysphagia (PSD), based on randomized controlled trials (RCTs). METHODS: A comprehensive search was conducted from inception to present across Chinese [(China National Knowledge Infrastructure (CNKI), VIP Chinese Science and Technology Periodical Database (VIP), Wanfang Data Knowledge Service Platform (WFSD), Chinese Biology Medicine Database (CBM)] and international databases (PubMed, Embase, Web of Science, and Cochrane Library). RCTs investigating validated SETCM therapy modalities (e.g., herbal patches, iontophoresis, compresses, and fumigation) for PSD were included. All herbal components were taxonomically validated using the Kew Medicinal Plant Names Service (MPNS). The control group received conventional therapy (rehabilitation, nursing, and medication). The experimental group received SETCM therapies alone or combined with conventional care. The risk of bias in eligible studies was assessed using the Cochrane risk-of-bias tool. A meta-analysis was performed using RevMan 5.4. Stratified subgroup analyses were conducted based on stroke lesion location (supratentorial vs. brainstem) and intervention type. RESULTS: Twenty-five RCTs (n = 2,159 patients; SETCM therapies group = 1,152, control group = 1,007) were included. The meta-analysis demonstrated significantly greater benefits in the SETCM therapies group for: overall response rate (OR = 3.28, 95% CI [2.49, 4.31]); overall cure rate (OR = 2.36, 95% CI [1.84, 3.02]); water swallowing test (WST) score (MD = -0.65, 95% CI [-1.23, -0.06]); and SWAL-quality-of-life (SWAL-QOL) score (MD = 25.61, 95% CI [20.54, 30.67]). The SETCM therapies group also demonstrated superior results in videofluoroscopic swallow study (VFSS) scores, modified Barthel index (MBI), serum albumin (ALB), prealbumin (PA), gugging swallowing screen (GUSS), activities of daily living (ADL), and functional dysphagia scale (FDS) scores, nasogastric tube removal success rate, as well as lower Nutritional Risk Screening 2002 (NRS 2002) scores, reduced aspiration incidence, and shorter nasogastric tube indwelling time. Safety analysis (three studies) reported mild skin irritation (erythema and pruritus) in 2.1% of cases. CONCLUSION: SETCM therapies significantly improved swallowing function, nutritional status, and clinical outcomes in patients with PSD. Efficacy exhibited neuroanatomical specificity: Acupoints are preferred for cerebral hemisphere lesions, while herbal iontophoresis is the best choice for brainstem involvement. These findings support the integration of targeted SETCM therapies into PSD rehabilitation. However, the evidence is limited by methodological biases, necessitating high-quality RCTs for confirmation. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024599344.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Zhang J, Kang X, Zhao J, et al. Systematic review and meta-analysis of specific external Chinese herbal medicines for post-stroke dysphagia: efficacy and clinical implications. Front Pharmacol. 2025. PMID: 40959452. doi:10.3389/fphar.2025.1635090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。